SCHEMBL7534084

SCHEMBL7534084

COc1ccc(S(=O)(=O)c2c(F)c(F)c(NS(=O)(=O)C(F)(F)F)c(F)c2F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.47
HSD11B1 P28845 1/20 0.47
RAPGEF4 Q8WZA2 1/20 0.44
FFAR4 Q5NUL3 4/20 0.44
PTGS1 P23219 2/20 0.43
PTGS2 P35354 2/20 0.43
SLC22A12 Q96S37 1/20 0.43
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP12 P39900 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA13 Q8N1Q1 1/20 0.42
GAA P10253 2/20 0.42
KMT2A Q03164 3/20 0.41
PTPN1 P18031 1/20 0.41
MEN1 O00255 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7535746 0.85 PKM (0.51) PKMHSD11B1RAPGEF4FFAR4MMP2
SCHEMBL7535604 0.83 ALDH1A1 (0.50) FFAR4PTGS1PTGS2SLC22A12CA12
SCHEMBL12434593 0.82 PKM (0.69) PKMHSD11B1RAPGEF4FFAR4MMP2
SCHEMBL7537217 0.82 KMT2A (0.44) PKMFFAR4PTGS1PTGS2CA1
SCHEMBL7536275 0.81 KMT2A (0.60) FFAR4GAAKMT2AMEN1GABRG2
SCHEMBL7533090 0.81 PKM (0.67) PKMHSD11B1RAPGEF4FFAR4MMP2
SCHEMBL7535534 0.80 TUBB1 (0.40) PKMFFAR4PTGS1PTGS2MMP2
SCHEMBL7534906 0.75 PKM (0.58) PKMHSD11B1RAPGEF4FFAR4MMP2
SCHEMBL7535730 0.75 PKM (0.58) PKMHSD11B1RAPGEF4FFAR4MMP2
SCHEMBL7533431 0.73 PKM (0.47) PKMHSD11B1RAPGEF4MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 PKM 3140/4885HSD11B1 106/4885RAPGEF4 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.